The West Australian government has recognised the good work Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is doing by sponsoring the company to attend BIO Korea 2023.
Recce is developing a new class of synthetic anti-infectives and was selected as one of three West Australian companies to attend BIO Korea 2023 and participate in the Australian Biotech Mission.
Sponsorship includes registration and participation fees, one-on-one meetings and VIP participation in networking events.
The conference is one of the largest for the sector.
In 2022, the conference had companies and attendees from more than 50 countries and 22,401 on-site visitors. Attendees include the world’s leading biotech companies, investors, executives, business experts and researchers.
For Recce, the conference is a chance to develop important business opportunities including partnership opportunities, government networking, clinical research collaborations, regulatory guidance and clinical trial expansion.
About BIO Korea
The conference is designed to invigorate and grow the global bio-health industry.
Through various programs of BIO Korea 2023 including Conferences, Business Partnering, Exhibition, and Invest Fair, participants will exchange the newest bio-health trends and technology as well as get the global expansion business opportunity with various international academics, professionals, and CEOs of the global bio-health field.
The conference will be held on May 10-12, 2023 at COEX in Seoul, South Korea.
About Recce
Recce is developing a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Its anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.